Recently, Nuohui Health announced the completion of two patent transfers related to nasopharyngeal cancer screening with Sun Yat-sen University, and will cooperate with Professor Jia Weihua and his team of the Affiliated Cancer Hospital of Sun Yat-sen University to develop screening products for nasopharyngeal cancer "a diagnostic marker of nasopharyngeal cancer" and "a nasopharyngeal brush", and the current early diagnosis rate of nasopharyngeal cancer is expected to increase.
Xinhua News Agency
Nasopharyngeal carcinoma refers to malignant tumors that occur in the epithelium of the nasopharynx mucosa, and the incidence rate in the high incidence areas of southern China is as high as 20 to 30/100,000. 80% of the world's NASOPHARY patients are concentrated in South China and Southeast Asia, of which Guangdong and Hong Kong rank first in the world. The 5-year survival rate of early nasopharyngeal carcinoma is more than 90%, but the treatment methods of advanced nasopharyngeal carcinoma are not ideal, which seriously affects the quality of life of patients, and there is an urgent need for effective screening and treatment methods.
Professor Jia Weihua is an authoritative expert on the pathogenesis, susceptibility genes and treatment of nasopharyngeal carcinoma in China. She took the lead in carrying out large-scale genetic epidemiological research on nasopharyngeal carcinoma at home and abroad, and on the basis of genome-wide scanning and analysis of high-incidence families of Nasopharyngeal cancer in Guangdong, she first located the chromosomal region of the susceptibility gene of nasopharyngeal cancer in Guangdong population; in the research field of nasopharyngeal carcinoma susceptibility gene, she conducted substantial cooperative research with internationally renowned medical research institutions such as Johns Hopkins University, and won the key project of international scientific and technological cooperation of the Ministry of Science and Technology and two funding from the National Institutes of Health (NIH) of the United States The long-term trend of nasopharyngeal carcinoma incidence and mortality in areas with high incidence of nasopharyngeal carcinoma was studied, and the incidence and mortality of nasopharyngeal carcinoma were systematically reported in international journals.
"The current early diagnosis rate of NASOPHARY is less than 30%, and the main reason is the lack of suitable large-scale screening techniques and products. Professor Jia Weihua's research over the years has found a number of innovative biomarkers, laying a solid theoretical foundation for the development of nasopharyngeal cancer screening products. We are very honored to accept two technology patents by Professor Jia and his team, and will work side by side with Professor Jia and her team in the future to explore the research and development of nasopharyngeal cancer screening products. Zhu Yeqing, executive director and CEO of Nuohui Health, said that the development of nasopharyngeal cancer screening products will combine NUO Health's proprietary multi-omics molecular diagnostic technology platform to achieve high-sensitivity detection of nasopharyngeal carcinoma through the joint detection of a variety of biomarkers. Nuohui Health's medical laboratory in Guangzhou will undertake the landing of relevant research work, which will strongly support its scientific research and user service capacity building in the Guangdong-Hong Kong-Macao Greater Bay Area.
Written by: Nandu reporter Zeng Wenqiong
Intern: Xu Ziqing
![Nuohui Health's ghost tube was approved to obtain the first certificate of Helicobacter pylori consumer self-test[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)